• 6 July 2011

    Endosense and GE Healthcare have entered into a joint development agreement to integrate the contact-force data provided by Endosense into GE’s CardioLab electrophysiology recording and Innova imaging platforms. By combining their technologies, the companies are working on the development of an all-in-one system for performing catheter ablation procedures for the treatment of cardiac arrhythmias.

  • 30 May 2011

    NovaShunt AG has launched a new corporate identity and product branding to support its goal of leadership in the area of fluid management within the body. The company will now operate as Sequana Medical AG as it prepares for the upcoming launch of the ALFApumpTM System in Europe.

  • 9 May 2011

    Santhera Pharmaceuticals (SIX: SANN) announced today that it will present first analyses of the 2-year open-label study (DELPHI-E) evaluating Catena® for the treatment of Duchenne Muscular Dystrophy. The findings indicate that Catena® can slow the decline in respiratory function associated with patients as they age. Data will be presented on May 9, 2011 in Lille, France at the 4th International Congress of Myology [1].

  • 5 May 2011

    NovaShunt AG, a private Swiss medical device company with innovative fluid management technologies, announced today that it has raised CHF 23.7 million (about $25 million) in a Series B preferred share financing round co-led by BioMedInvest AG, Entrepreneurs Fund and Capricorn Health-tech Fund. Existing investors, NeoMed and VI Partners, were also significant participants in the new financing and NeoMed retains its role as the lead investor and largest shareholder of NovaShunt.

  • 5 May 2011

    Endosense and BIOTRONIK SE & Co. KG have announced that Endosense’s TactiCath1 contact-force sensing ablation catheter has been used to perform more than one thousand patient cases of atrial fibrillation (AF) in Europe within the last twelve months. The commercial milestone, which coincided with the companies’ presence at the Heart Rhythm Society’s 32nd Annual Scientific Sessions in San Francisco, marks a significant achievement for both organizations. Endosense pioneered the field of contact-force sensing in catheter ablation with the development of its TactiCath catheter and accompanying Tactisys system, the second generation of which were launched in April 2010. BIOTRONIK has built and is continuing to grow the market for the TactiCath as its exclusive distributor in Europe as well as Latin America, Canada, Africa and the Middle East.